San Mateo, United States
Selonterra, Inc. is a biopharma and biotechnology startup that aims to revolutionize the treatment of neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s diseases, by leveraging human genetics and gene regulatory networks. Established in 2017 and based in the San Francisco Bay Area, the company has secured significant venture capital funding, including a recent $2.50M grant investment from The Michael J. Fox Foundation for Parkinson's Research in October 8, 2024.
Selonterra's innovative approach involves uncovering how genetic variants associated with neurodegenerative disorders impact gene expression, particularly through the alteration of transcription factor binding sites. The company's Alzheimer’s disease program focuses on the development of small molecules targeting a previously unexploited druggable target, promising to revolutionize therapy for this condition.
The startup sets itself apart by combining deep expertise in startups with a global network of specialized collaborator companies, enabling the application of cutting-edge technologies in a capital-efficient manner. With its clear vision and strategic funding partnerships, Selonterra, Inc. is poised to make a significant impact in the biopharma and biotechnology industries, offering new hope for patients with neurodegenerative disorders.
